Larazotide

Larazotideis a peptide which is an orally active zonulin antagonist. Larazotide shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide can be used for the research of celiac disease and infection[1][2].

Product Specifications

CAS Number

[258818-34-7]

UNSPSC

12352209

Target

Gap Junction Protein

Type

Peptides

Related Pathways

Cytoskeleton

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/larazotide.html

Purity

99.26

Solubility

H2O : 2.5 mg/mL (ultrasonic)

Smiles

NCC(NCC(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N1[C@@H](CCC1)C(NCC(O)=O)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C32H55N9O10

Molecular Weight

725.83

References & Citations

[1]Di Micco S, et al. Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation. Int J Mol Sci. 2021 Aug 30;22 (17) :9427.|[2]Gopalakrishnan S, et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012 May;35 (1) :86-94.